About Acorda
Acorda is a Healthcare company based in Ardsley (United States) founded in 1995, and was acquired by Merz in May 2024. Engaged in the development and commercialization of therapies that improve neurological function. Acorda has raised $66.5 million across 3 funding rounds from investors including J P Morgan, ABN AMRO and Easton Capital Investment Group. The company has 109 employees. Acorda has completed 3 acquisitions, including Biotie, Civitas Therapeutics and Neuronex. Acorda offers products and services including AMPYRA, INBRIJA, and ARCUS Technology. Its focus areas include Life Sciences, Drug Delivery, Nanoparticle Based and Neurology. Its legal entity is Acorda Therapeutics Inc. Its competitors include Biogen, Neurocrine and PTC Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Acorda Therapeutics was founded in 1995 as a biopharmaceutical company focused on the identification, development, and commercialization of treatments for neurological conditions, including multiple sclerosis and spinal cord injury. Operations center on products such as Ampyra, approved in 2010 for improving walking in MS patients, and Zanaflex Capsules for spasticity management. The company is headquartered in Ardsley, United States, within the healthcare sector.
- Headquarters Ardsley, United States
- Employees 109
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website acorda.com
- Social LinkedIn X Facebook
- Acquired by Merz (May 2024)
- Legal Name Acorda Therapeutics Inc.
- Annual Revenue$118.57 M (USD)-8as on Dec 31, 2022
- Net Profit-$65.92 M (USD)37as on Dec 31, 2022
- EBITDA-$35.34 M (USD)55as on Dec 31, 2022
- Total Equity Funding$66.5M (USD)
in 3 rounds
- Latest Funding Round$31.5M (USD), Post-IPO
Oct 2006
- InvestorsJ P Morgan
& 4 more
- Employee Count109
- Investments & AcquisitionsBiotie
& 2 more
- Acquired byMerz
(May 2024)
Products & Services of Acorda
Acorda offers a comprehensive portfolio of products and services, including AMPYRA, INBRIJA, and ARCUS Technology.
Drug for improving walking in multiple sclerosis patients.
Inhalation powder for managing Parkinson's disease symptoms.
Technology platform for neurological drug delivery systems.
Funding Insights of Acorda
Acorda has successfully raised a total of $66.5M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $31.5 million completed in October 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $66.5M
- Total Rounds 3
- Last Round Post-IPO — $31.5M
- First Round $55M
(May 2003)
- Investors Count 4
All 3 funding rounds of Acorda with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2006 | $31.5M | Post-IPO | – | – | – |
| Mar 2004 | $11.5M | Series C | – | – | – |
| May 2003 | $55M | Series C | – | – |
5 investors in total: 5 institutional.
Investors in Acorda
Acorda has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include J P Morgan, ABN AMRO and Easton Capital Investment Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| eastoncapital.com | ||||
Capital is invested in life science innovations for healthcare transformation. | tvm-capital.com | Munich, Germany | ||
ABN AMRO is recognized as a personal bank in the digital era. | 1991 | abnamro.com | Amsterdam, Netherlands | |
Comprehensive financial services are provided to corporations and individuals. | 1799 | jpmorgan.com | New York, United States | |
Merz Therapeutics is focused on developing treatments for chronic health conditions. | merztherapeutics.com | Frankfurt, Germany |
Investor details for Acorda
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Acorda
39 people are tracked at Acorda (13 in leadership, 3 in board & advisors, 23 in team); the tracked headcount is 109.
| Name | Role | Group |
|---|---|---|
Denise Duca | Executive Vice President, Human Resources | Leadership |
Susan Veres | Vice President, Facilities & Business Risk Management | Leadership |
Farzin Daneshnia | Director Of Market Development | Leadership |
Roberta Peterson | Senior Director Of Market Access | Leadership |
Viktoriia Chernobrovina | Head Of Financial Planning And Analysis, Treasurer | Leadership |
David Squillacote | VP & Head Of Medical Affairs | Leadership |
Jonathan Kuhn | Director Of Global & Brand Marketing | Leadership |
Maria Verastegui | Executive Director Marketing Brand Experience Design | Leadership |
Peter Henderson | Vice President Compliance | Leadership |
Ira Starr | Senior Director, Compliance And Validation | Leadership |
Mike Marrah | Regional Business Director | Leadership |
Michael Arnold | Senior Director Commercial Training & Leadership Development | Leadership |
Dave Hughes | Senior Regional Business Director - West Coast Region | Leadership |
Peder K. Jensen | Board Member | Board & advisors |
Tom Burns | Board Member | Board & advisors |
Sandra Panem | Board Member | Board & advisors |
Betsy Smith | Executive Area Business Manager | Team |
Kerry McNutt | Executive Area Business Manager | Team |
Byron Coleman | Executive Area Business Manager | Team |
John Walters | Sr. Account Business Manager | Team |
19 more people are available in the full profile.
Complete people profiles for Acorda
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Acorda
Acorda has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Biotie, Civitas Therapeutics and Neuronex.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Drugs for neurodegenerative and psychiatric disorders are developed by Biotie. | biotie.com | Turku, Finland | 1998 | Jan 2016 | $363M | |
Inhaled pulmonary therapies for Parkinson's motor fluctuations are developed. | civitastherapeutics.com | Chelsea, United States | 2009 | Sep 2014 | $525M | |
Nasal spray formulation of diazepam is developed for seizure disorders. | neuronexinc.com | Morrisville, United States | 2010 | Feb 2012 | $6.8M |
Complete acquisition details for Acorda
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Acorda
8 dated milestones of Acorda across 29 years, from founding to its latest funding, stage changes and deals.
- Founded Acorda is founded.
- Funding First funding round of $55.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $31.5M.
- Acquisition Acquires Neuronex.
- Acquisition Acquires Civitas Therapeutics.
- Acquisition Acquires Biotie.
- Exit Acquired by Merz.
Competitors of Acorda
Acorda has 3 listed competitors in our database, 3 of them funded. They include Biogen, Neurocrine and PTC Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of Acorda
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Acorda
Websites that share an audience with Acorda (acorda.com).
- Global rank#13,560,187
among all websites
- Category rank#8,457
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.1
- DevicesDesktop 24% · Mobile 76%
Websites whose visitors overlap most with Acorda. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| acadia-pharm.com | 100% | View details | |||
| merck.com | 100% | 656.8K | #78,842 | View details | |
| genzyme.com | 86% | View details | |||
| emergentbiosolutions.com | 86% | 35.6K | #745,411 | View details | |
| amicusrx.com | 84% | 20.4K | #1,355,769 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 24 similar websites and full traffic analytics for Acorda
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 24 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Acorda (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Acorda
Complete news archive for Acorda
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acorda
Acorda was founded in 1995 and raised its 1st funding round 8 years after it was founded.
Acorda is headquartered in Ardsley, United States. It is registered at Ardsley, New York, United States.
Acorda is a funded company, having raised a total of $66.5M across 3 funding rounds to date. The company's 1st funding round was a Series C of $55M, raised on May 2003.
Acorda has 109 employees.
Annual revenue of Acorda is $118.57M as on Dec 31, 2022.
Acorda Therapeutics was founded in 1995 as a biopharmaceutical company focused on the identification, development, and commercialization of treatments for neurological conditions, including multiple sclerosis and spinal cord injury. Operations center on products such as Ampyra, approved in 2010 for improving walking in MS patients, and Zanaflex Capsules for spasticity management. The company is headquartered in Ardsley, United States, within the healthcare sector.
Acorda's top competitors include PTC Therapeutics, Neurocrine and Biogen.
Acorda offers AMPYRA, INBRIJA, and ARCUS Technology.
Acorda has made 3 acquisitions, including Biotie, Civitas Therapeutics, and Neuronex.
Acorda has 5 investors. Key investors include J P Morgan, ABN AMRO, Easton Capital Investment Group, TVM Capital Life Science, and Merz Therapeutics.
Acorda operates through Acorda Therapeutics Inc..
Yes. Acorda was acquired by Merz in May 2024.